TrialInternational clinical psychopharmacology2015

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.

Paula L Jacobsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.